About us
Team
Investors
Science
Pipeline
Partnerships
News & Events
Press releases
Contact
Press releases
February 24, 2025
Tay Therapeutics Strengthens BET Asset Portfolio with Key IP Assignment from Dundee University
READ MORE >
September 27, 2024
Tay Therapeutics announces Publication of New Patent for Readthrough Agents Targeting Genetic Diseases
READ MORE >
June 13, 2024
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
READ MORE >
June 5, 2024
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
READ MORE >
October 1, 2023
Tay Therapeutics Secures £0.35 Million Innovate UK grant to investigate therapeutic applications of Readthrough compounds
READ MORE >
LOAD MORE
BACK TO TOP
